Innophore Competitors

Novozymes has combined with Chr. Hansen to become Novonesis: linkedin.com/company/novonesis. This global biosolutions company of 10,000 people is transforming how the world produces, consumes and lives. In 30-plus industries, its biosolutions help businesses meet their needs and the needs of our planet. Novozymes was formed in 2000 when Novo Nordisk split into three companies: Novo Nordisk A/S, Novozymes A/S and Novo A/S. Novozymes was the world leader in biological solutions with a commitment to Rethink Tomorrow. It served 130 markets with enzymatic, microbial and advanced protein solutions. The company’s solutions enabled higher agricultural yields, low-temperature washing, energy-efficient production, renewable fuel and many other benefits. In December 2022, Novozymes and Chr. Hansen entered into an agreement to create a leading global biosolutions partner by combining the two companies. The goal was to unleash the full potential of biosolutions and generate significant value for all stakeholders and society. The combination was completed on January 29, 2024 and Novonesis was born. The name means ‘a new beginning’ and is derived from the Greek word ‘genesis’. It reflects a new era where we’ll better our world with biology. You can find Novonesis on LinkedIn here: linkedin.com/company/novonesis. Novozymes A/S, part of Novonesis Group.

Codexis is redefining what is possible in therapeutic development and manufacturing, leading the technology revolution with efficient, high-quality, and commercially proven solutions. The company’s manufacturing platforms consistently outperform legacy methods, enabling the development of therapeutic possibilities that were previously out of reach. With a proven track record, proprietary technology, and unrivalled scientific expertise, Codexis advances beyond conventional boundaries. More than a solutions provider, Codexis serves as a trusted long-term partner, committed to driving progress across complex therapeutic development and manufacturing.

Since its inception in 1994, Zymo Research has been proudly serving the scientific community by providing innovative, reliable, and high quality research tools at affordable prices. Our vision..."The Beauty of Science is to Make Things Simple" is now truer than ever. Whether it's epigenetics, DNA, RNA, E. coli, or yeast based research, our philosophy remains the same: To provide the highest quality products in the industry while ensuring they are both simple to use and reliable in their performance. Zymo Research is historically recognized for its innovation of high quality nucleic acid purification technologies. Under the branding DNA Purification Made Simple™ and RNA Purification Made Simple™, our technologies are pushing the limits of what is possible with nucleic acid isolation. As The Epigenetics Company™, Zymo Research has also received much attention for its rapidly expanding portfolio of epigenetics products and services. It is our objective to develop and provide the most comprehensive set of tools for DNA, RNA, and epigenetic research and analysis available today. Thousands of peer-reviewed scientific publications from researchers around the world feature our technologies. Through innovation, our scientists have made streamlined DNA methylation detection possible, pioneered the micro-elution column for DNA and RNA purification, developed the simplest and the most sophisticated methods for high-quality plasmid DNA purification, and patented the first RNA purification directly from Trizol without phase separation among many other leading technologies in the industry. At Zymo Research, we are committed to quality and guarantee that all of our products and service will meet and exceed your expectations. We pledge to be honest and responsible for everything we do with you. We will treat you as we would like to be treated. Together, we will build a brighter future.